文献速递肿瘤 PET/CT核素与放射性配体治疗

在健康志愿者和前列腺癌患者中使用GRPR拮抗剂68Ga-RM26进行PET显像

PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients.
PubMed 文献 · J Nucl Med · 2017-11-09

研究评估了GRPR拮抗剂68Ga-RM26 PET的安全性、生物分布与辐射剂量学,并在28例前列腺癌患者中评估诊断价值,其中22例与激动剂68Ga-BBN PET/CT直接对比。结果显示68Ga-RM26耐受良好,总有效剂量当量为0.0912±0.0140 mSv/MBq,68Ga-RM26 PET/CT检测原发灶和转移灶优于68Ga-BBN,且SUV与GRPR表达水平呈显著正相关(P<0.001)。

要点

  • 68Ga-RM26给药耐受良好,随访2周内未见或报告不良反应症状。
  • 总有效剂量当量为0.0912±0.0140 mSv/MBq,有效剂量为0.0657±0.0124 mSv/MBq。
  • 68Ga-RM26 PET/CT检测原发灶和转移灶优于GRPR激动剂68Ga-BBN PET/CT。

核心结论

  • 研究表明GRPR拮抗剂68Ga-RM26具有安全性和显著效能。
  • 68Ga-RM26 PET/CT在检测原发前列腺癌和转移灶方面具有重要价值。
  • 68Ga-RM26有望作为优于GRPR激动剂的显像标志物来评估前列腺癌中GRPR的表达。

研究设计与样本

  • 研究纳入5名健康志愿者验证68Ga-RM26的安全性并计算剂量学。
  • 共招募28例前列腺癌患者(17例新诊断、11例治疗后),均签署书面知情同意。
  • 所有患者静脉注射1.85 MBq(0.05 mCi)/kg体重的68Ga-RM26后15-30分钟行PET/CT。
  • 其中22例患者(11例新诊断、11例治疗后)在1周内行68Ga-BBN PET/CT进行对比。
  • 在2周内行99mTc-MDP骨扫描进行对比,并对肿瘤样本行GRPR免疫组化染色。

主要发现

  • 所有受试者对68Ga-RM26给药耐受良好,操作过程中及2周随访期间未观察到或报告不良反应症状。
  • 17例新诊断前列腺癌患者中,68Ga-RM26 PET/CT显示15个肿瘤为前列腺局限阳性,SUVmax为6.49±2.37。
  • 11例接受前列腺切除术或近距离放疗(联合或不联合雄激素剥夺治疗)的患者中,68Ga-RM26 PET/CT在3例患者中检出8个转移淋巴结,SUVmax为4.28±1.25;在8例患者中检出21个骨病灶,SUVmax为3.90±3.07。
  • 与68Ga-RM26 PET/CT相比,GRPR激动剂68Ga-BBN PET/CT检出的原发灶和淋巴结转移灶更少,示踪剂摄取也更低。
  • 68Ga-RM26 PET的SUV与GRPR表达水平呈显著正相关(P<0.001)。

关键数值与推荐

  • 68Ga-RM26的总有效剂量当量为0.0912±0.0140 mSv/MBq,有效剂量为0.0657±0.0124 mSv/MBq。
  • 新诊断前列腺癌患者中68Ga-RM26 PET/CT阳性前列腺局限病灶的SUVmax为6.49±2.37。
  • 治疗后患者中转移淋巴结的SUVmax为4.28±1.25,骨病灶的SUVmax为3.90±3.07。
  • 68Ga-RM26 PET的SUV与GRPR表达水平呈显著正相关(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study was designed to analyze the safety, biodistribution, and radiation dosimetry of a gastrin-releasing peptide receptor (GRPR) antagonist PET tracer, 68Ga-RM26; to assess its clinical diagnostic value in prostate cancer patients; and to perform a direct comparison between GRPR antagonist 68Ga-RM26 and agonist 68Ga-BBN. Methods: Five healthy volunteers were enrolled to validate the safety of 68Ga-RM26 and calculate dosimetry. A total of 28 patients with prostate cancer (17 newly diagnosed and 11 posttherapy) were recruited and provided written informed consent. All the cancer patients underwent PET/CT at 15-30 min after intravenous injection of 1.85 MBq (0.05 mCi) per kilogram of body weight of 68Ga-RM26. Among them, 22 patients (11 newly diagnosed and 11 posttherapy) underwent 68Ga-BBN PET/CT for comparison within 1 wk. 99mTc-MDP (methylene diphosphonate) bone scans were obtained within 2 wk for comparison. GRPR immunohistochemical staining of tumor samples was performed. Results: The administration of 68Ga-M26 was well tolerated by all subjects, with no adverse symptoms being noticed or reported during the procedure and at 2-wk follow-up. The total effective dose equivalent and effective dose were 0.0912 ± 0.0140 and 0.0657 ± 0.0124 mSv/MBq, respectively. In the 17 patients with newly diagnosed prostate cancer, 68Ga-RM26 PET/CT showed positive prostate-confined findings in 15 tumors with an SUVmax of 6.49 ± 2.37. In the 11 patients who underwent prostatectomy or brachytherapy with or without androgen deprivation therapy, 68Ga-RM26 PET/CT detected 8 metastatic lymph nodes in 3 patients with an SUVmax of 4.28 ± 1.25 and 21 bone lesions in 8 patients with an SUVmax of 3.90 ± 3.07. Compared with 68Ga-RM26 PET/CT, GRPR agonist 68Ga-BBN PET/CT detected fewer primary lesions and lymph node metastases as well as demonstrated lower tracer accumulation. There was a significant positive correlation between SUV derived from 68Ga-RM26 PET and the expression level of GRPR (P < 0.001). Conclusion: This study indicates the safety and significant efficiency of GRPR antagonist 68Ga-RM26. 68Ga-RM26 PET/CT would have remarkable value in detecting both primary prostate cancer and metastasis. 68Ga-RM26 is also expected to be better than GRPR agonist as an imaging marker to evaluate GRPR expression in prostate cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang J, Niu G, Fan X, et al. PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients. J Nucl Med. 2017. PMID: 29123014. doi:10.2967/jnumed.117.198929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。